Sidney Taurel
Sidney Taurel
Sidney Taurelis a Moroccan-born American businessman. He is the former Chairman and Chief Executive Officer of Eli Lilly and Company. He became chief executive officer in July 1998 and chairman of the board of directors on January 1, 1999. He was succeeded as chief executive officer by John C. Lechleiter on April 1, 2008. He now serves as an advisor at Moelis & Company...
abide actions activities although assure business charged committed continue deeply designed ensuring ethical federal fully governing government highest laws legal practices reflect regret remain resulted seriously standards steps
We deeply regret the 1998 conduct, which has resulted in a federal misdemeanor charge. We take seriously our responsibilities to abide by all the laws governing our business practices and are committed to ensuring our employees' actions reflect the highest legal and ethical standards of conduct. Although the government has not charged Lilly with any unlawful intent, we will continue to take steps designed to assure that Lilly's promotional activities remain fully compliant.
access affordable assistance earthquake ease employees ensure essential forward gave groups halt health hurricane improve offered patients save seniors share six spread stepped suffering urgent year
In a year of urgent needs, Lilly and its employees stepped forward with extraordinary efforts. To ease the suffering of hurricane and earthquake victims, we gave essential medicines, cash, and supplies. To ensure that seniors and low-income patients had affordable access to drugs, we offered six patient assistance programs. And to halt the spread of multi-drug-resistant tuberculosis, we partnered with the World Health Organizations and other groups to share expertise, improve treatment, and save lives.
dose patient
the right dose of the right drug to the right patient at the right time.
address bring closely committing company continue deliver fda innovative medicines necessary order patients promise quickly resources work
I am committing all the necessary resources of the company to address these issues, ... We will continue to work closely with the FDA in order to deliver on our promise to bring these innovative new medicines to patients as quickly as possible.
combined continues dependent five fully growth introduced last less line major percent performance product products prozac rate sales
As our product line continues to become more diversified, we have become less dependent on Prozac performance. Major products introduced in the last five years accounted for fully one-third of our sales in 1999 and had a combined growth rate of 41 percent during the year.
destiny execute help structure
Now that we've done all this, our destiny is in our hands. It's up to us to perform. This new structure will help us better execute our strategy.
earnings forward grow growth looking percent products share
Looking forward to 2006, our newer products should grow to about 24 percent of revenues and earnings per share should grow 8 to 11 percent, representing top-tier growth for large-cap pharmaceutical companies.
ability add area bar behind bench dedication drive increase leadership leaves performance pivotal raise strong throughout transform valued
Charlie's leadership was pivotal in our drive to increase productivity in every part of Lilly. His ability to transform our organization and raise the bar in every area of performance has been invaluable. His dedication to leadership development is also evident. He leaves behind a strong bench of valued leaders who add value throughout the company.
bringing earnings half sales second stronger
As we expected, the second half of 2005 is bringing stronger sales and earnings growth,
forward join leadership role senior vital
He is very well-prepared for the vital role he will play, and I look forward to having him join our senior leadership team.
existing extensions growth less line next overall product products prozac quarters recent rely sales several
Our overall growth for the next several quarters will be generated from newer product sales, line extensions of existing products and recent product launches, ... As a result, we will rely less on Prozac sales growth.
commitment execution faster grow quarter rate reflect results sales strong
Our strong bottom-line results in the first quarter reflect the execution on our commitment to grow sales at a faster rate than our expenses.
help means products weather
That means up to 10 products that will be launched between 2001 and 2004, which will help us weather the storm,
broad built business challenges charlie company financial help internal judgment past reputation sound steer strong
During his tenure, Charlie used his broad business experiences and sound judgment to help steer the company through many challenges over the past decade. Through Charlie's leadership, we have built a world-class financial organization and strengthened Lilly's reputation for sound financial operations, transparency in our financial reporting, and strong internal controls.